Search company, investor...
Search

Predict your next investment

Private Equity
ottercapital.com

See what CB Insights has to offer

Investments

30

Portfolio Exits

3

About Otter Capital

Otter Capital is a private equity financing firm.

Otter Capital Headquarters Location

755 Page Mill Road Suite A200

Palo Alto, California, 94304,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Otter Capital News

Botanical Solution Raises $6.1 Million In Series A Funding

Jan 31, 2022

Botanical Solution recently announced it raised $6.1 million in Series A funding. These are the details. Botanical Solution (BSI) — an innovator of sustainable, consistent, and cost-effective Advanced Botanical Materials for agricultural and pharmaceutical applications — announced it has successfully closed $6.1 million in a Series A round led by Otter Capital. And this round of funding will enhance BSI’s value proposition by facilitating the geographic expansion of its current botanical-based products and the development of a new product pipeline derived from its proprietary biotech platform. For agricultural markets, this Series A round of funding will support the production and sales growth of BSI’s first commercially successful product marketed as BotriStop and its recently announced global brand Quillibrium, which is based on a tissue-cultured tree native to Chile called the Quillaja saponaria. This product has been used successfully on a wide variety of fruits and vegetables throughout Chile. And Quillibrium was launched in Peru last year with great success and will soon reach growers across Mexico through BSI’s main distribution partner Syngenta. Quillibrium is continuing regulatory progress in the US and will soon initiate registration in additional countries to expand its global footprint. This new funding round will also accelerate the market readiness of new botanical biopesticide products currently in later development stages and enable the expansion of BSI’s R&D pipeline. For pharmaceutical markets, BSI’s new funding round will vastly increase the quantity of Quillaja saponaria plants that can be grown at BSI’s labs and the sustainable production of billions of doses of gold standard adjuvant QS-21, traditionally obtained from old native trees that are increasingly affected by climate change and strict deforestation laws in Chile. QS-21 is used in Covid-19 and malaria vaccines, as well as a blockbuster shingles vaccine. With this funding round, BSI will become a major supplier of pharmaceutical-grade QS-21. KEY QUOTES: “The BSI team is really excited to welcome Otter Capital. We are happy to reconfirm the strong commitment from our current investors, as well. BSI is building strong foundations to deliver the world’s most advanced botanical biopesticides and ensure the supply of the gold standard vaccine adjuvant QS-21.” — BSI CEO Gastón Salinas “I am excited to partner with BSI. BSI has established a strong market presence via distribution agreements with Syngenta and effective, profitable products. BSI’s product development platform is efficient and scalable. Botanical products have excellent consistency and BSI’s approach is truly sustainable. These products have applications in two very large markets – agriculture and pharmaceuticals. I am very impressed by the team at BSI and the progress they have made with limited resources under Gastón’s leadership.” — John Pasquesi, Managing Member at Otter Capital

Otter Capital Investments

30 Investments

Otter Capital has made 30 investments. Their latest investment was in Botanical Solution as part of their Series A on January 1, 2022.

CBI Logo

Otter Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/18/2022

Series A

Botanical Solution

$6.1M

Yes

3

12/1/2020

Series D - II

NewLeaf Symbiotics

$22M

No

2

2/24/2020

Series D

NewLeaf Symbiotics

$20M

No

2

3/26/2019

Series E

Subscribe to see more

$99M

Subscribe to see more

10

3/13/2018

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/18/2022

12/1/2020

2/24/2020

3/26/2019

3/13/2018

Round

Series A

Series D - II

Series D

Series E

Series D

Company

Botanical Solution

NewLeaf Symbiotics

NewLeaf Symbiotics

Subscribe to see more

Subscribe to see more

Amount

$6.1M

$22M

$20M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

2

2

10

10

Otter Capital Portfolio Exits

3 Portfolio Exits

Otter Capital has 3 portfolio exits. Their latest portfolio exit was Arena Solutions on December 14, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/14/2020

Acquired

$99M

5

11/18/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/6/2012

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/14/2020

11/18/2020

7/6/2012

Exit

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

5

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.